New hope for muscle stiffness: experimental drug PGN-EDODM1 enters Mid-Stage trial
NCT ID NCT06667453
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an investigational drug called PGN-EDODM1 in 24 adults with myotonic dystrophy type 1, a condition causing muscle stiffness and weakness. Participants receive multiple doses of the drug or a placebo by IV to check safety and how the body processes it. The goal is to see if the drug is safe and tolerable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PGN-EDODM1
What this could lead to
If successful, this could point toward a treatment that controls symptoms of myotonic dystrophy type 1, like muscle stiffness and weakness.
What could go wrong
This is an early Phase 2 trial with only 24 participants, so results may not apply to everyone. The drug is still experimental and may not work or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOTONIC DYSTROPHY 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CIUSSS du Saguenay-Lac-Saint-Jean
RECRUITINGChicoutimi, Quebec, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Montreal Neurological Institute
RECRUITINGMontreal, Quebec, H3A 2B4, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Newcastle Upon Tyne Hospitals
RECRUITINGNewcastle upon Tyne, NE7 7DN, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ottawa Hospital Research Institute (OHRI)
RECRUITINGOttawa, Ontario, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Pacific Clinical Research Network Auckland
ACTIVE_NOT_RECRUITINGTakapuna, Auckland, 0622, New Zealand
-
Salford Royal Hospital
RECRUITINGSalford, England, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University College London Hospitals NHS Foundation Trust
RECRUITINGLondon, UK, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Calgary
RECRUITINGCalgary, Alberta, T2N 4Z6, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••